Rotmensch J, Atcher R W, Hines J, Toohill M, Herbst A L
Division of Chemistry, Argonne National Laboratory, Illinois 60439.
Gynecol Oncol. 1989 Dec;35(3):297-300. doi: 10.1016/0090-8258(89)90067-x.
We are investigating the potential use of short-lived alpha-emitting radionuclides for the treatment of ovarian carcinoma. These radionuclides transfer dense high ionizing linear energy (high LET) over a short path length without dependence upon cellular oxygen. The alpha-emitting radionuclides chosen were lead-212 and bismuth-212 which are readily available. The radiosensitivities of two ovarian carcinoma cell lines (OVC-1 and OVC-2) was greater with 212Pb and 212Bi than with X-ray therapy. D0, inversely related to the radiosensitivity, was 155 and 240 rads for OVC-1 and OVC-2, respectively. With 212Pb or 212Bi, the slope of the survival curves was steeper. The D0 was 75 and 70 rads after 212Pb and 85 and 95 rads after 212Bi treatment for OVC-1 and OVC-2, respectively. The relative biological effectiveness with alpha irradiation was two to four times greater than with X rays. Unlike low-LET irradiation (i.e., X rays and gamma emitters) the cells had no ability to accumulate or repair sublethal damage. From these experiments it is concluded that a greater therapeutic advantage may be gained with alpha-emitting radionuclides than X rays. Further development of these nuclides may provide for a new form of therapy.
我们正在研究使用短寿命发射α粒子的放射性核素治疗卵巢癌的潜在用途。这些放射性核素在短程内传递密集的高电离线性能量（高传能线密度），且不依赖细胞氧。所选用的发射α粒子的放射性核素是易于获得的铅 - 212和铋 - 212。两种卵巢癌细胞系（OVC - 1和OVC - 2）对212Pb和212Bi的放射敏感性高于X线治疗。与放射敏感性呈反比的D0值，OVC - 1和OVC - 2分别为155和240拉德。使用212Pb或212Bi时，存活曲线的斜率更陡。对于OVC - 1和OVC - 2，212Pb治疗后的D0值分别为75和70拉德，212Bi治疗后的D0值分别为85和95拉德。α射线照射的相对生物效应比X射线大两到四倍。与低传能线密度照射（即X射线和γ射线发射体）不同，细胞没有积累或修复亚致死损伤的能力。从这些实验得出结论，发射α粒子的放射性核素可能比X射线具有更大的治疗优势。这些核素的进一步开发可能会提供一种新的治疗形式。
